Empagliflozin

Dr. McPhee: This is not quite the best option in this case. Empagliflozin can an excellent drug, particularly for patients with certain co-morbidities, such as heart failure, chronic kidney disease, and established or high atherosclerotic cardiovascular (ASCVD) risk. It can also help when weight loss is a goal. There is no compelling cardiorenal indication to start it ahead of another drug that is more cost-effective and could also provide benefits in preventing complications and reducing weight.

Please go back and reconsider.

  • Ο ασθενής σας δίνει λεπτομερές ιατρικό ιστορικό [undo]
  • Test de identificare a glucozei [undo]
  • Επιλογή 1: A και Γ είναι σωστά [undo]
  • No, although the patient and caregiver consent, the patient has no known mutation and complete clinical response [undo]
  • Start complement inhibition (eculizumab/ravulizumab) [undo]
  • Increasing the substrate concentration [undo]
  • Carbimazole [undo]
  • виклик 112 [undo]
  • Exploring the Desire to Remain Productive Despite Chronic Illness [undo]
  • LB [undo]
  • Admission [undo]
  • Bisoprolol [undo]
  • Επιτρέπετε στη μητέρα να φέρει τον Rory πίσω όταν είναι εφικτό [undo]
  • Ενημερώνετε την αστυνομία και τους ζητάτε να βρουν τον Rory και να τον επιστρέψουν στο νοσοκομείο [undo]
  • Observing the wrong section of the tip [undo]
  • Digoxin (digitalis, positive inotropic drug) [undo]
  • Θέλεις να κάνει υπέρηχο καρδιάς πρώτα [undo]
  • Ο ασθενής έχει αυξημένα ηπατικά ένζυμα [undo]
  • MSA [undo]
  • Sensation test [undo]
  • Activates somatostatin receptors [undo]
  • Yes, because the patient and caregiver consent, the patient has no known variant and complete clinical response [undo]
  • Ignore the wound complaint and focus solely on blood glucose. [undo]
  • ΧΕΙΡΟΥΡΙΚΗ ΕΚΤΙΜΗΣΗ [undo]
  • A microscope that uses electron source to magnify objects [undo]
  • Empagliflozin [undo]

Map: Michael Green_GEMD_2 (1116)
Node: 21112
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway